Fate Therapeutics (FATE) Enterprise Value (2016 - 2025)
Fate Therapeutics (FATE) has disclosed Enterprise Value for 14 consecutive years, with -$203.7 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 27.02% year-over-year to -$203.7 million, compared with a TTM value of -$203.7 million through Dec 2025, up 27.02%, and an annual FY2025 reading of -$203.7 million, up 27.02% over the prior year.
- Enterprise Value was -$203.7 million for Q4 2025 at Fate Therapeutics, up from -$215.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$203.7 million in Q4 2025 and bottomed at -$790.1 million in Q1 2021.
- Average Enterprise Value over 5 years is -$423.1 million, with a median of -$380.7 million recorded in 2023.
- The sharpest move saw Enterprise Value plummeted 288.69% in 2021, then soared 37.31% in 2025.
- Year by year, Enterprise Value stood at -$615.9 million in 2021, then grew by 29.17% to -$436.2 million in 2022, then grew by 27.75% to -$315.2 million in 2023, then increased by 11.46% to -$279.1 million in 2024, then grew by 27.02% to -$203.7 million in 2025.
- Business Quant data shows Enterprise Value for FATE at -$203.7 million in Q4 2025, -$215.4 million in Q3 2025, and -$222.8 million in Q2 2025.